BMC Gastroenterology

RESEARCH

Open Access

Energy metabolism alteration and gene expression reprogramming in a cell model of high fat load non-alcoholic fatty liver disease

Tianran Zhou[1,2], Yuhang Zhou[1,3], Cagla Cömert[2], Xiao-Yu Zhou[4], Lin Lin[4,5], Lars Bolund[4,6], Johan Palmfeldt[2], Yonglun Luo[4,5,6*], Peter Bross[2*] and Guangdong Tong[1*]

Abstract

Background Metabolic rewiring plays a crucial role in the energy metabolism of hepatocytes during steatosis. However, the precise alterations in energy metabolism remain unclear. The aim of this study was to investigate the effects of lipid exposure on cellular energy metabolism and gene expression in a cellular model of non-alcoholic fatty liver disease (NAFLD).

Methods and results We induced hepatocyte steatosis in the hepatocyte cell line Huh7 via treatment with high levels of palmitate and oleate for 24 h. We then analysed transcriptomics, proteomics, mitochondrial phenotypes, and cellular energy metabolism. Fatty acid-treated cells presented significant accumulation of lipid droplets and reduced viability. Real-time bioenergetics analyses demonstrated a shift towards mitochondrial respiration for energy production, accompanied by a reduction in glycolytic adenosine triphosphate (ATP) production. However, the overall rate of ATP production remained constant. RNA-seq analysis revealed altered expression of 149 transcripts associated with lipid storage and catabolism, whereas 172 proteins presented significantly altered levels and were enriched in RNA processing and splicing functions. Two genes, ACAA2 and PLIN2, were significantly altered at both the transcript and protein levels and may be crucial for maintaining mitochondrial function in early non-alcoholic fatty liver (NAFL).

Conclusions Our NAFLD model demonstrated that the reprogramming of genes involved in lipid storage and catabolism is crucial for early NAFL pathogenesis development. This study offers new insights with valuable implications for designing future research into novel therapeutic strategies.

Keywords Mitochondrial function, Energy metabolism, Gene expression reprogramming, Cell models, NAFLD

*Correspondence:
Yonglun Luo
alun@biomed.au.dk
Peter Bross
peter.bross@clin.au.dk
Guangdong Tong
tgd755@163.com

Full list of author information is available at the end of the article

Introduction

Non-alcoholic fatty liver disease (NAFLD) encompasses non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis, which significantly increase the risk of cirrhosis and hepatocellular carcinoma [1]. The condition typically begins with hepatic steatosis and progresses to advanced liver disease, exerting a profound impact on patients' quality of life while imposing substantial burdens on families, healthcare systems, and economies.

In recent decades, research has indicated that NAFLD is associated with metabolic disorders [2, 3]. Obesity and type 2 diabetes are major risk factors for NAFLD, with the accumulation of free fatty acids (FFA) in the liver as an initial trigger [4]. Despite extensive research, the exact pathogenesis of NAFLD, including the mechanisms triggering the transition between stages, is still unclear, and there are no recommended treatments available [3]. Whether FFA deposition affects energy metabolism by reprogramming hepatocyte gene expression remains incompletely elucidated. Mitochondria serve as the primary sites for fatty acid degradation, and mitochondrial activity and the capacity to store lipid droplets determine a cell's ability to handle high levels of fatty acids. Indeed, mitochondrial metabolic dysfunction has been reported to be associated with the development of NAFLD [5],

In this study, we modelled early NAFL pathogenesis by exposing the human cell line Huh7 to a high concentration of a mixture containing both saturated (palmitic acid) and unsaturated (oleic acid) fatty acids for 24 h. Our objective was to investigate how this affects both the structure and function of cellular mitochondria as well as cellular energy metabolism. Additionally, we conducted transcriptome and protein expression analyses to monitor the reprogramming of gene expression. This article was previously published as a preprint (BioRxiv) [6].

Materials and methods

Cell culture and treatment

Human hepatocellular carcinoma cell line (Huh7) was cultured in Dulbecco's modified Eagle's medium (DMEM) with high glucose (Sigma) supplemented with 10% fetal bovine serum (Biowest), 2 mM L-Glutamine (Sigma), 10,000 U/mL penicillin and 10 mg/mL streptomycin (Sigma) at 37 °C under 5% CO_2 in a 95% humidified atmosphere. The cells were exposed for 24 h to a 1200 μM exogenous fatty acid mixture containing palmitic (P0500, Sigma) and oleic acid (O1008, Sigma). The mixture was freshly prepared before each experiment. In brief, fatty acid stock solution was added to prewarmed complete medium (molar ratio of palmitic acid: oleic acid = 1:2, complexed with 300 μM fatty acid-free bovine serum albumin (BSA) (A8806, Sigma) to induce NAFLD at the stage of steatohepatitis as previously described [7].

Cell viability and in vitro cytotoxicity assay

Cell viability was assessed via a Cell Counting Kit-8 (CCK-8) (Sigma) for quantitation of the number of viable cells in proliferation and cytotoxicity assays. Briefly, 8×10^3 cells/well were seeded in a 96-well microplate and pre-incubated for 24 h. The medium was then removed, and the cells were treated with medium with or without FFA for another 24 h. The cells were washed twice with DMEM followed by the addition of 10 μL of CCK-8 in 100 μL of DMEM and incubation at 37 °C for 80 min. The absorbance at 450 nm was measured with a Synergy H1 Hybrid Multi-Mode Reader (BioTek) and Gen5 software.

Oil red O and coomassie brilliant blue staining

The cells were washed twice in phosphate buffer saline (PBS) and fixed with 10% formalin for 1 h. The cells were then incubated in 60% isopropanol for 5 min. The isopropanol was discarded, and the cells were incubated in Oil Red O Working Solution (Sigma) for 20 min. Oil Red O Working Solution was prepared by mixing 0.5% Oil Red O in isopropanol and water at a ratio of 3:2. After discarding the Oil Red O solution, the cells were washed 5 times with sterile ultrapure water. The absorbance at 510 nm was measured by a Synergy H1 Hybrid Multi-Mode Reader (BioTek) and Gen5 software. The cells were counterstained with 0.25% Coomassie Brilliant Blue R-250 dye (AKH Reagent) for 5 min and washed 3 times with sterile ultrapure water to visualize the cytoskeleton. Images were taken with a light microscope camera (ZEISS), both with a 10x objective and a 40x objective (Fig. 1B).

Seahorse analysis of cellular bioenergetics

The real-time oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were measured via a Seahorse XFe96 extracellular flux analyzer (Seahorse Bioscience). The experiments were performed according to the manufacturer's instructions, with minor modifications, as specified below. The OCR and ECAR were measured via a Seahorse XF Cell Mito Stress Test Kit (Agilent Technologies). A total of 1×10^4 cells/well were plated onto 7 μg/mL Poly-D-Lysine coated [8] Seahorse XF cell culture microplates and allowed to attach for 4 h. The medium was then removed, and the cells were treated with DMEM with FFA or control medium for 24 h. Based on pilot experiments, we used the following procedure: after baseline measurements, oligomycin (1.5 μM), FCCP (0.65 μM), and rotenone plus antimycin A (Rot/AA) (0.5 μM) were sequentially injected into each well at the indicated time points. Three consecutive measurements were performed for each step/injection. After the OCR and ECAR were measured, the cells were stained with 2.5 μM Hoechst 33,342 for 55 min. Hoechst fluorescence was recorded via Cytation 1, the number of cells per well was calculated via Seahorse XF Imaging and Cell Counting



Fig. 1 High free fatty acids (FFA) treatment results in lipid droplet accumulation and moderately reduced viability but has no significant effect on the degree of apoptosis or reactive oxygen species production. **A** Workflow for the establishment of the in vitro non-alcoholic fatty liver disease (NAFLD) Huh7 cell model. DMSO: dimethyl sulfoxide. PA: palmitic acid, OA: oleic acid. **B** Representative images from light microscopy analysis of FFA-treated cells and control cells, stained with Oil Red O solution after fixation (scale bar = 20 μm). **C** Quantification of Oil Red O staining. The absorbance values were recorded at 510 nm and normalized to those of the untreated cells. n=3. **D** Viability of Huh7 cells measured by a Cell Counting Kit-8 assay after 24 h of exposure to FFA. n=3. **E** High-throughput flow cytometry and microscopy analysis. Control and model cells were stained with MitoSOX Red, MitoTracker Green, and Hoechst as described in the Materials and Methods and analysed by ImageStreamX Mark II multispectral imaging flow cytometer. The inset shows an example of phase-contrast images of representative cells, and the respective fluorescence channel pictures are shown in the MitoTracker Green (green colour), MitoSOX (red colour), and merged channels.Quantification of the average fluorescence intensity of MitoTracker Green per cell, MitoSOX per cell, and Hoechst 33342 per cell in Huh7 cells with or without FFA treatment for 24 h. n=4.All numeric results are expressed as the mean value of triplicate samples normalized to the untreated cells ± SD (error bars). *p < 0.05, **p < 0.01

Software, and the OCR and ECAR data were normalized to the number of cells. The data were further analyzed via Seahorse XFe Wave software and exported to Microsoft Excel. The OCR is reported in pmols/min/1000 cells, and the ECAR is reported in mpH/min/1000 cells.

The MitoATP Production Rate (pmol ATP/min/1000 cells), glycoATP Production Rate (pmol ATP/min/1000 cells), total ATP Production Rate (pmol ATP/min/1000 cells), % Glycolysis, % Oxidative Phosphorylation, and XF ATP Rate Index were calculated from normalized real-time OCR (pmols/min/1000 cells) and ECAR (mpH/min/1000 cells) data from the Seahorse XF Cell Mito Stress Test according to 11 equations in the manufacturer's ATP Rate Assay instructions.

Glycolytic rate assay parameters, including basal glycolysis (glycoPER) (pmol/min/1000 cells), basal proton efflux rate (PER) (pmol/min/1000 cells), % PER from glycolysis (basal) (%), and basal mitoOCR/glycoPER data, were calculated from real-time OCR, ECAR and predetermined CO_2 contribution factor according to the manufacturer's glycolytic rate assay user guide.

MitoTracker green live-cell staining

Huh7 cells were incubated at 37 °C with prewarmed (37 °C) 200 nM MitoTracker Green (Thermo Fisher) and 2.5 μM Hoechst 33,342 (Thermo Fisher) in Hank's balanced salt solution with calcium and magnesium (Gibco) simultaneously for 45 min. The staining solution was removed, and Hank's balanced salt solution was added to the cells. Live cell images were recorded immediately via a fluorescence microscope (EVOS® FL) with a 40x objective (Fig. S2).

Live cell staining and high-throughput imaging flow cytometry

Firstly, live cells were washed twice with warm PBS and then stained with prewarmed 5 μM MitoSOX Red (Thermo Fisher) for 10 min at 37 °C. Secondly, the cells were washed twice, stained with prewarmed 0.5% BSA/PBS containing 100 μM MitoTracker Green (Thermo Fisher) and 3.3 μM Hoechst 33,342 (Thermo Fisher) and incubated for 45 min at 37 °C. Thirdly, the cells were washed, lifted with trypsin/EDTA, centrifuged, and resuspended in 0.5% BSA/PBS. Compensation controls were prepared for each fluorochrome to make a standard compensation matrix file. A minimum of 10,000 Huh7 cells were acquired for analysis.

Samples were acquired via an ImageStreamX Mark II multispectral imaging flow cytometer (Amnis) equipped with INSPIRE ImageStreamX System software. The data were analysed via IDEAS image data exploration and analysis software version 6.3 (Amnis).

RNA library construction and mRNA-sequencing

Total RNA from control ($n = 3$) and model ($n = 3$) Huh7 cells was isolated with TRIzol reagent (Thermo Scientific), and the RNA concentration, purity and integrity were assessed with a Synergy H1 Hybrid Multi-Mode Reader (BioTek) and 2100 Bioanalyzer (Agilent Technologies). Total RNA samples were stored at − 80 °C until further analysis.

The construction and deep sequencing of RNA libraries were accomplished with the assistance of BGI Europe Co., Ltd. Briefly, by oligo(dT) selection, mRNA was enriched and purified from total RNA, followed by RNA fragmentation, reverse transcription, end repair, add base A, and adaptor ligation. After PCR amplification, the double-stranded PCR products were subjected to heat separation, cyclization (circularized by the splint oligo sequence), and DNA nano ball synthesis. The single-stranded circular DNAs were formatted as the final library for library quality assessment and subsequent PE100 (paired-end 100) sequencing. mRNA-sequencing was performed on a well-established DNBSEQ/MGISEQ2000 Technology Platform [9, 10] (BGI, Copenhagen, Denmark).

Transcriptome pipeline for mRNA-seq and gene-level differential expression analysis

The upstream pipeline includes quality control, adapter trimming, quality filtering, genome alignment, reads deduplication, and estimation of gene expression levels.

After removing duplicate reads from bam files, counting reads were used as a measure of gene expression by featureCounts, and raw data counts were normalized separately by transcripts per million (TPM) (reference of R script: https://github.com/t-arae/ngscmdr/blob/master/R/calc_rpkm.R), DESeq2 (version 1.30.1), and EdgeR (version 3.32.0) with trimmed mean of M value. The raw count data from RNA-seq were normalized by TPM [11] method for gene expression heatmap visualization. HISAT2 software (version 2.2.1) was used for mapping the mRNA-sequencing reads. Deduplication (Dedup) was performed by the Picard tool (version 2.23.8). GENCODE V35 was the selected annotation gene sets, and the GRCh38 primary assembly version was the selected human genome. The number of annotated genes in the selected gene sets (GENCODE V35) was 60,715 (including 19,983 coding genes, 16,899 non-coding genes, and 1,881 pseudogenes). Gene expression levels were quantified with the above reads/annotations by featureCounts without gene types filtering. During the differential expression analysis, the gene types and symbols were annotated and added to the raw counts data, after which the coding genes were selected for further analysis.

Raw count data normalization, protein-coding genes selection, and differential expression analysis were

performed by DESeq2 R/Bioconductor package [12]. The fold change, $\log_2$(fold change) and *p*-value were calculated, and the gene type and other annotations were reported by biomaRt. Genes with a TPM < 10 were removed, and $P < 0.05$ was selected as the cut-off criterion to identify differentially expressed genes via the DESeq2 method. Differentially expressed gene analysis was performed via EnrichR.

Sample preparation for proteomics

Protein samples were labelled with a TMT sixplex isobaric mass tagging kit (Thermo Scientific) according to the manufacturer's protocol, and the subsequent proteomics analyses were performed essentially as previously described [13]. In brief, 80 µg of total protein was reduced and alkylated with tris(2-carboxyethyl)phosphine and iodoacetamide, followed by overnight acetone precipitation. After the pellet was redissolved, the proteins were digested overnight with trypsin (Promega). The resulting peptides were labelled with the TMT sixplex isobaric mass tag, and the six samples—three treated and three control samples—were pooled. Peptide fractionation by isoelectric focusing was performed as previously described [14]. The pool of labelled peptides was dissolved in 10 mM phosphoric acid, pH 3.0, and 25% acetonitrile before strong cation exchange purification via an strong cation exchange cartridge (Phenomenex). After washing, drying, elution, and drying by a SpeedVac vacuum concentrator overnight, vacuum-dried labelled peptide pools were rehydrated and fractioned into ten fractions by isoelectric focusing with an immobiline dry strip, pH 3–10, 18 cm (GE Healthcare). Peptides were extracted and dissolved in 5% acetonitrile and 0.5% trifluoroacetic acid and further purified via C18 spin columns (Thermo Scientific) according to the manufacturer's protocol. After elution, the samples were dried by a SpeedVac vacuum concentrator and stored at -20 °C until nano Liquid chromatography-tandem mass spectrometry (LC–MS/MS) analysis.

NanoLC-MS/MS and proteomics database searches

LC–MS/MS was performed, as previously described [15], on an EASY nanoLC-1000 coupled to a Q Exactive™ HF-X Quadrupole-Orbitrap™ Mass Spectrometer (Thermo Scientific). A precolumn (Acclaim PepMap 100, 75 µm × 2 cm, Nanoviper, Thermo Scientific) and an analytical column (EASY-Spray column, PepMap RSLC C18, 2 µm, 100 Å, 75 µM × 25 cm) were used to trap and separate peptides via a 170 min gradient (5–40% acetonitrile, 0.1% formic acid). The MS instrument was operated in positive mode, and higher-energy collisional dissociation with a collision energy of 35 was applied for peptide fragmentation. The full-scan (MS1) resolution was 60,000, and the automation gain control target was set at 1×10^6 with a scan range between 392 and 1,500 m/z. Data-dependent analysis was applied to fragment up to 12 of the most intense peaks in MS1. The resolution for fragment scans (MS2) was set at 45,000, with the first fixed mass at 110 m/z and the automation gain control target at 1×10^5. Dynamic exclusion was set at 15 s, and unassigned and + 1 charge states were excluded from fragmentation. Each sample was analysed twice via LC–MS/MS. Peptides identified with more than nine peptide spectrum matches in the first analysis were excluded from fragmentation in the second analysis. All 20 (= 2 × 10) LC–MS analyses of the study were merged and submitted for database search for protein identification and quantification in Proteome Discoverer 2.3 (Thermo Scientific) via the Sequest algorithm, with 20,422 reviewed *Homo sapiens* UniProt sequences as the reference proteome. The precursor and fragment mass tolerances were set at 10 ppm and 20 mmu, respectively. The oxidation of methionine was set as a dynamic modification, and static modifications included carbamidomethylation of cysteines and TMTsixplex labelling of lysine and peptide N-terminus. The co-isolation threshold was set at 45%, and the identification false discovery rate was set to 0.01.

Bioinformatics analysis of differential gene expression at the protein level

$P < 0.05$ and $|\log_2(\text{fold change})| > 0.263034$ were selected as the cut-off criteria to identify differentially expressed proteins [16]. Donut charts were drawn, and differentially expressed proteins with statistical significance were highlighted in volcano plots via the EnhancedVolcano package (Blighe K, Rana S, Lewis M (2022)). Enhanced Volcano: Publication-ready volcano plots with enhanced colouring and labelling. R package version 1.16.0, https://github.com/kevinblighe/EnhancedVolcano). Hierarchical clustering was performed via Morpheus (https://software.broadinstitute.org/morpheus).

UniProt keywords, gene ontology (GO) analysis, including biological process (BP), cellular component and molecular function groups, and KEGG pathways enrichment analysis of the differentially expressed proteins were performed via the EnrichR DAVID bioinformatics resources [17, 18], with all the detected high-confidence proteins used as background. A count ≥ 2 and a modified Fisher Exact *p* (EASE score) ≤ 0.1 were used as thresholds for DAVID functional annotation analysis.

The MitoCarta 3.0 datasets, which contains detailed information on the 1136 human mitochondrial genes, including submitochondrial localization and pathways [19], were used to identify human mitochondrial proteins.

A pivot chart was used to show the frequency distribution of $\log_2$(fold change) values for transcriptomics and proteomics. A TPM ≥ 10 was used as a threshold for fold

change for the transcriptomics dataset only for genes commonly quantified in transcriptomics and proteomics analyses. The pivot table was generated via Microsoft Excel, and the pivot graph was generated via GraphPad Prism 9.

A PPI cluster network of the 8 coregulated genes and proteins was generated and exported via the STRING 11.0 online tool [20] (https://string-db.org/). Network type = full STRING network, required score = low confidence (0.150), FDR stringency = medium (5%), organism: *Homo sapiens*, network clustering = k-means clustering, number of clusters = 3 were used as thresholds and parameters for STRING analysis.

Statistical analysis

Normally distributed data are expressed as the means ± SDs around the means, and nonnormally distributed data are expressed as percentiles. We checked whether the data conformed to a normal distribution. For normally distributed data, nonpairwise comparisons were performed via Student's *t* test. A nonparametric test was used for nonnormally distributed data. Calculations were performed via SPSS 20.0. A p value of < 0.05 was considered statistically significant. Hierarchical clustering analysis was performed via Morpheus (https://software.broadinstitute.org/morpheus). Correlation analysis was performed via GraphPad Prism 9.

Results

Establishment of the Huh7 cell NAFLD model

To investigate the cellular responses of hepatocytes to high FFA loads, we utilized a cell-based NAFLD model that was previously described by Chavez-Tapia et al. [7]. For the model, the human liver cancer cell line Huh7 was treated for 24 h with a 1:2 mixture of palmitic and oleic acid (total FA concentration of 1200 μM) bound to BSA (Fig. 1A). Oil Red O staining clearly revealed increased accumulation of lipid droplets within FFA-treated Huh7 cells (Fig. 1B). Oil Red O staining revealed a significant increase in lipids in FFA-treated cells (Fig. 1C). Following Oil Red O staining, Coomassie Brilliant Blue staining was performed to visualise the cytoskeleton (Fig. S1). This clarified that the significant increase in Oil Red O staining in the model group was not due to a reduction in cells in the control group. CCK-8 analysis revealed a significant decrease in the viability of the FFA-treated cells (Fig. 1D).

To get an overview of the effects of FFA treatment on mitochondria, we first performed fluorescence microscopy imaging of mitochondria with MitoTracker Green. This indicated that there are no significant alterations in mitochondrial size and morphology in cells treated with FFA (Fig. S2). To investigate the functions associated with mitochondrial dysfunction, we conducted high-throughput single-cell imaging by employing MitoTracker Green staining to assess mitochondrial volume, MitoSOX Red staining to measure mitochondrial superoxide levels, and Hoechst 33342 staining to evaluate apoptosis. Our findings demonstrated that FFA treatment did not significantly affect mitochondrial volume and had no notable effect on superoxide levels, both in terms of the mean intensity and the mean intensity normalized to MitoTracker Green staining (Fig. 1E). Furthermore, Hoechst 33342 staining, an indicator of apoptosis [21], remained unaltered in NAFLD model cells (Fig. 1E).

FFA treatment alters cellular bioenergetics in the Huh7 cell NAFLD model

We next investigated whether NAFLD model cells displayed changes in key parameters of mitochondrial and cellular energy metabolism via the Seahorse XFe96 metabolic analyzer and the MitoStress Test protocol (Fig. 2A and B). Our data revealed that FFA-treated cells presented increased OCR, reflecting increased mitochondrial respiration, and decreased PER, reflecting decreased glycolytic lactate production. Calculation of key metabolic parameters revealed that FFA treatment induced a significant increase ($p = 0.047$) in basal respiration (data not shown), and there were no significant changes in maximal respiration ($p = 0.391$) (data not shown).

We also calculated the ATP production rates from respiration and glycolysis (see Materials and Methods). This finding revealed that mitochondrial ATP production was increased (17%) and that glycolytic ATP production was concomitantly decreased (14%) in the FFA-treated cells (Fig. 2C), resulting in an increased ATP rate index (Fig. 2D). However, there was no significant change in the total ATP production rate, indicating that the shift between the two ATP production pathways was balanced.

Effects of FFA treatment on the gene expression of Huh7 cells

To identify transcripts and proteins that are differentially expressed in response to high-FFA treatment, we performed mRNA-seq and mass spectrometric proteomics analysis (Fig. 3). Three biological replicates of control and FFA-treated cells, each cultured in parallel on different days, were analysed. Figure 3A and B present an overview of the number of quantitated and significantly increased and decreased transcripts and proteins, respectively. The volcano plots in Fig. 3B illustrate the distributions of the fold changes and p values for the 12,410 quantitated protein-coding transcripts and the 4,110 quantitated proteins. Please refer to the materials and methods section for details on the inclusion criteria. By applying cut-off criteria of a p value < 0.05 and a minimum fold change of 20% increase or decrease ($|(\log2(\text{fold change})| \geq$



Fig. 2 FFA-treated Huh7 cells are shifted to a more oxidative/less glycolytic phenotype. Real-time oxygen consumption rates (OCR) and proton excretion rates (PER) were measured in live Huh cells via a Seahorse XFe96 metabolic analyzer. Using the Cell Mito Stress Test assay, oligomycin, carbonyl cyanide-4 (trifluoromethoxy) phenylhydrazone (FCCP), rotenone, and antimycin (Rote/AA) were sequentially injected at the indicated time points. The data were normalized to the number of cells, as determined by Hoechst staining. **A** Representative OCR and (**B**) PER tracings of Huh7 cells with or without FFA treatment. **C** Adenosine triphosphate (ATP) production rates from mitochondrial respiration and glycolysis were calculated from the OCR and PER traces as described in the Materials and Methods. **D** ATP rate index showing the ratio of mitochondrial to glycolytic ATP production. All numeric values are expressed as the mean value of triplicate samples ± SD (error bars). *$p < 0.05$, **$p < 0.01$

0.263034), we identified 149 differentially expressed transcripts in the FFA-treated group compared with the control group. Using the same cut-off criteria for proteomics analysis, we found that 172 proteins were differentially expressed in the FFA-treated group.

Enrichment analysis

Enrichment analysis (EASE score < 0.1) conducted via EnrichR [22] (https://maayanlab.cloud/Enrichr/) revealed significant enrichment of GO BP terms associated with cholesterol/lipid metabolism in the 149 differentially expressed transcripts (Fig. 3C, left panel). The volcano plots display the names of the genes encoding the top 15 upregulated and downregulated transcripts (Fig. 3B, left panel). Notably, a majority of these transcripts encode proteins involved in lipid metabolism, transport, and regulation. The downregulated transcripts included those encoding the fatty acid desaturases SCD and FADS2 and proteins involved in lipid synthesis (FASN, ACACA) and lipid handling and transport (MYLIP, ABCA1). In contrast, upregulated transcripts encode proteins engaged in lipid storage (PLIN2, ACSL5) and import long-chain fatty acids into mitochondria (CPT1A, SLC25A20). Several transcripts encoding proteins implicated in metabolic regulation are either upregulated (CREB3L3, KLF10RBP2) or downregulated (SREBF1, ANGPTL3, INSIG1, MID1IP1). This illustrates the rewiring of lipid metabolism to cope with the increased load of fatty acids. mRNAs encoding proteins in the endoplasmic reticulum membrane involved in feedback control of cholesterol synthesis (SREBF2 and INSIG1) [23], transcripts encoding proteins related to the carnitine shuttle for importing fatty acids into the mitochondria (CPT1A and SLC25A20), ACAA2 involved in both fatty acid degradation and ketone body metabolism, and HMGCS2 involved in the mevalonate pathway for lipid and cholesterol synthesis were also upregulated.

EnrichR analysis of the 172 differentially expressed proteins revealed a more diverse landscape of GO BP terms encompassing 'regulation' or 'signalling', as well as RNA handling and splicing, for both the up- and downregulated proteins (Fig. 3C, right panel). No



Fig. 3 Overview of the results of the transcriptome (left panel) and proteome (right panel) analyses of FFA-treated Huh7 cells and controls. **A** Donut charts summarizing the RNA-seq and proteomics data. **B** Volcano plots of all quantitated protein-coding transcripts and all quantitated proteins. Differentially expressed transcripts and proteins are highlighted as red dots. The 15 up- and downregulated transcripts and proteins with the lowest p values are labelled. Genes differentially regulated at both the transcript and protein levels are labelled with red letters. **C** Bioinformatics analysis of FFA-treated Huh7 cell proteomics data. Bar charts showing the p value (bars) and count (lines) of the top 10 significantly enriched gene ontology biological process terms from EnrichR analysis of significantly regulated transcripts (left) and proteins (right); green: upregulated; orange: downregulated

significant enrichment was observed in terms related to lipid metabolism. The volcano plot highlights the top 15 up- or downregulated proteins. Notably, one pattern emerged upon inspection: sequential modification of the protein N-terminus involving N-terminal methionine removal (METAP2) and acetylation at the new N-terminus by NAA25. In addition, several proteins involved in vesicle trafficking were differentially regulated: EIPR1, VPS26A, and RAB8B were upregulated, whereas STX18 was downregulated. A series of proteins associated with transcription, RNA splicing, and transport exhibited differential expression: ALYREF was upregulated, whereas NELFB, BRD8, PRPF38A, and LUC7L3 were downregulated. Proteins involved in lipid storage in droplets (PLIN2) were significantly upregulated, whereas the fatty acid desaturases SCD and FADS2, which are involved in lipid metabolism, were downregulated. Notably, the



Fig. 4 A core of proteins and their encoding transcripts are consistently regulated. Comparison of the results of RNA-seq and proteomics analysis. The log2fold changes (proteomics: horizontal axis; transcriptomics: vertical axis) are plotted. The stippled lines indicate the fold changes thresholds (Significantly different values of $p < 0.05$ and fold change +/- 20% (DESEQ $p < 0.05$)). Red: upregulated at both levels; blue: downregulated at both levels. The inset shows an interaction cluster network obtained from STRING analysis for four proteins which both the transcripts and proteins are differentially regulated. Edges represent protein–protein associations, and line colors indicate different types of interaction evidence

results of these gene transcriptome and proteome analyses were correlated.

Comparison of transcriptome and proteome changes

To differentiate transcriptional regulation from other mechanisms impacting protein levels, we compared the fold changes in transcript abundance with those in protein abundance. Nearly all the quantified proteins were measured at the transcript level, whereas less than half of the quantified transcripts were assessed at the protein level. Examination of the transcript counts revealed that most transcripts not quantified at the protein level corresponded to genes expressed at low levels (data not shown). One possible explanation for this observation is that proteomics analysis may less sensitive. Additionally, other factors—such as post translational modifications, protein stability, limitations in the dynamic range of mass spectrometry, or biases introduced during sample preparation—could also account for the absence of corresponding protein measurements for certain transcripts. The scatter plot in Fig. 4 illustrates the fold changes in the expression of the 4,109 genes quantified at both the transcript and protein levels. Eight genes that exhibited significant regulation (p value < 0.05 and fold change ≥ 20%) at both levels are annotated. Among these genes, four genes were upregulated at both the transcript and protein levels, three genes were downregulated, and one (PPIB) was found downregulated at transcript level and upregulated at protein level (Fig. S3). Notably, five of the genes consistently regulated at the transcript and protein levels are involved in lipid metabolism and transport: two involved in metabolism of unsaturated fatty acids (FADS2, SCD), one involved in fatty acid oxidation (ACAA2), one involved in lipid storage (PLIN2), and one involved in lipid transport (LIMA1). Protein–protein interaction analysis via STRING revealed a cluster comprising four of these proteins (FADS2, SCD, PLIN2, and ACAA2), as shown in Fig. 4. Only one of the protein products of these genes, according to the MitoCarta 3.0 database [19] localized to mitochondria.

Discussion

Despite extensive research, the molecular pathological mechanisms underlying hepatocyte steatosis induced by high lipid loads remain poorly understood. This knowledge gap has impeded the design and development of targeted therapies aimed at delaying or counteracting pathogenesis. Insufficient capacity to handle excess fatty acids via lipid storage and increased fatty acid catabolism has been reported as an initial trigger in several studies, potentially leading to inflammatory responses and fibrotic signalling [5, 24, 25]. Chavez-Tapia et al. analysed the effects of 600 μM and 1200 μM free fatty acids (oleic acid/palmitic acid molar ratio 2:1) on Huh7 for 24 h. The study revealed a dose-dependent increase in the

inflammatory cytokine IL-8 mRNA expression, with a significant increase observed from 600 μM to 1200 μM. No significant changes were observed for the inflammatory cytokine TNF-α mRNA at 600 μM while exposure to 1200 μM resulted in up-regulation. The release of IL-8 from cells in the culture medium was increased in a dose-dependent manner at both FFA doses [7]. To further investigate the pathogenesis of NAFLD during its early stages, we employed a cellular model system exposed to a high lipid load and conducted comprehensive investigations into its effects on bioenergetics, mitochondrial function, and the regulation of gene expression.

The results showed that this model could induce increased lipid deposition in hepatocytes (Fig. 1B and C) and significantly decrease cell viability (Fig. 1D). Using real-time metabolic analysis with the Seahorse XFe96 extracellular flux analyzer, we explored the effects of 1200 μM FFA-treatment on cellular and mitochondrial energy metabolism. The NAFLD model cells exhibited alterations in pivotal parameters of mitochondrial and glycolytic ATP production. Seahorse XFe96 extracellular flux analysis experiments demonstrated that a high lipid load increased mitochondrial respiration (Fig. 2C), likely through increased metabolism through fatty acid oxidation. However, total ATP generation rates were maintained by decreasing glycolytic ATP production (Fig. 2C). Similar to our results, a previous study reported that supplementation with free fatty acids (0.3 mM oleic acid/0.2 mM palmitic acid) slightly increased maximal respiration compared with that in HepG2 cells [26]. Conversely, when solely supplemented with oleic acid, Huh7 cell models presented significant reductions in basal respiration levels, ATP production, maximum respiration capacity, and proton leakage [27], indicating that different fatty acids can elicit distinct cellular metabolic responses.

The significant increase in mitochondrial respiration following exposure to elevated levels of lipids is likely due to the production of reduction equivalents of NADH and FADH2 by mitochondrial fatty acid oxidation, which transfers electrons into the respiratory chain, increasing respiratory ATP production. Simultaneous reduction in glycolytic ATP production balanced overall cellular ATP generation, which remained unaltered (Fig. 2C). These findings suggest that lipid accumulation stimulates a switch in the balance between glycolysis and respiration (Fig. 2D). Additionally, our study revealed that FFA treatment did not significantly affect mitochondrial volume and had no discernible effect on mitochondrial superoxide levels or the degree of apoptosis (Fig. 1E). These findings are inconsistent with those of certain previous studies reporting increased oxidative stress [28, 29]. This could be because we measured mitochondrial superoxide levels, whereas other studies measured other oxidative stress indicators and/or differences in the duration of treatment. Balancing reactive oxygen species production upon prolonged increases in respiration (> 24 h) may exhaust cellular antioxidant mechanisms. In the early stages of NAFLD, increasing mitochondrial fatty acid degradation in hepatocytes may serve as a protective mechanism against steatosis by preventing further damage caused by excessive lipid deposition.

We then investigated whether the shift in ATP production from the mitochondrial and glycolytic pathways was due to alterations in the expression of relevant genes and whether the high fat load induced gene expression reprogramming in other cellular pathways. Our transcriptome and proteome analyses revealed no significant regulation of transcripts or proteins related to mitochondrial respiration or cytosolic glycolysis. Thus, the observed bioenergetic changes are likely due to posttranslational modifications or regulation at the metabolite level. A total of 149 differentially expressed transcripts were identified in the group that had received FFA treatment compared to controls and a proteome analysis revealed 172 differentially expressed proteins in the NAFLD cell model (Fig. 3A). In accordance with the findings of Seahorse, our bioinformatics analysis from our omics data also revealed that FFA-treated cells exhibited metabolic alterations such as lipid metabolism. Among the significantly regulated transcripts and proteins, five are associated with processes related to lipid metabolism: two involved in unsaturated fatty acid synthesis (FADS2, SCD), one involved in fatty acid catabolism (ACAA2), one involved in lipid storage (PLIN2), and one involved in lipid transport (LIMA1) (Fig. 4). Protein–protein interaction analysis via STRING revealed a cluster containing four of these proteins (FADS2, SCD, PLIN2, and ACAA2) (Fig. 4).

PLIN2 and ACAA2 have previously been implicated in NAFLD. PLIN2 is a highly expressed lipid droplet component in the liver that has been shown to regulate inflammation and is upregulated in response to high-fat treatment and in NAFLD patients [30]. Decreased levels of PLIN2, which are mediated by chaperone-mediated autophagy, promote the degradation of lipid droplets, whereas PLIN2 overexpression stabilizes these droplets [31]. The observed up-regulation of PLIN2 in FFA-treated cells (Fig. 4) may be a response to increased storage capacity for fatty acids in lipid droplets. However, this beneficial effect on fatty acid storage capacity may come at the cost of an increased propensity for apoptosis. The observed increase in PLIN2 expression at both the mRNA and protein levels is consistent with published data [32]. These findings suggest that the upregulation of this gene may be associated with the stabilization of lipid droplets in hepatocytes.

The mitochondrial matrix is where ACAA2 is located in human mitochondria. ACAA2 is a thiolase that

catalyzes the fourth step in the fatty acid β-oxidation pathway, which involves cleaving medium- to long-chain fatty acids to produce acetyl-CoA and the remaining acyl-CoA chain. Additionally, it facilitates the condensation of two acetyl-CoAs into acetoacetyl-CoA, initiating ketone body synthesis. Upregulation of ACAA2 may increase fatty acid oxidation rates, leading to an increased supply of acetyl-CoAs for the tricarboxylic acid cycle and subsequently providing NADH and FADH reduction equivalents, which drive respiratory chain activity. This could explain our observed increase in mitochondrial ATP production during Seahorse metabolic measurements (Fig. 2C). Simultaneously, increased ketone body synthesis from excess acetyl-CoA might limit the increase in respiration by diverting a portion of these molecules towards ketogenesis. Previous research has demonstrated that ACAA2 plays a role in fatty liver disease [33]. Other methods such as qPCR, western blot and immunostaining are needed to further validate the proteomic and RNA-seq results. The precise mechanism by which the mitochondrial gene ACAA2 regulates metabolism in NAFLD hepatocytes may be a topic worthy of further detailed study.

In our study, the strongest enrichment observed in proteomics pertains to RNA processing and splicing (Fig. 3C). Interestingly, only a proportion of patients with NAFL progresses to steatohepatitis, fibrosis, cirrhosis and even ultimately hepatocellular carcinoma. Patients diagnosed with NAFL can also experience rapid progression to steatohepatitis with liver fibrosis. Furthermore, individuals with non-alcoholic steatohepatitis may progress directly to hepatocellular carcinoma without first developing liver fibrosis. Although the molecular mechanisms underlying the of heterogeneity in disease progression among patients with NAFLD remain unclear, previous studies have suggested that RNA processing and alternative splicing play a role in this phenomenon [34–36]. Additionally, prior research has indicated that dysregulated RNA polyadenylation contributes to metabolic impairment in NAFLD [37]. These findings may help elucidate our results.

In addition, the following limitations of our study must also be taken into consideration: our hepatic steatosis cell model can reveal mechanisms in hepatocytes only during the early stages of NAFLD. In this study, we exclusively utilized the immortalized human liver cancer cell line Huh7. In comparison to immortalized cell lines, primary hepatocytes more accurately mimic the cellular environment within the liver. However, primary hepatocytes rapidly dedifferentiate and lose their biological functions —such as mature metabolic capabilities—within a few days to a week in culture [38, 39]. Additionally, primary hepatocytes typically cannot survive beyond 2 weeks in 2-dimensional culture systems [40]. Furthermore, ethical considerations and the limited availability of human or animal liver samples pose significant challenges for conducting experiments that require adequate replicates. These obstacles limit the application of primary hepatocytes. The PH5CH8 and IHH cell lines are similar to primary hepatocytes in that they are immortalized but not cancerous. It has been established through previous studies that the PH5CH8 cell line and IHH cell line are suitable for glucose metabolism studies; however, they are not recommended for fatty acid metabolism or de novo lipogenesis studies [41]. The hepatoma cell lines Huh7 and HepG2 are commonly used in NAFLD studies [42]. The selection of Huh7 cells was driven by the capacity for robust and reproducible culturing, a feature that enabled the conducting of our complex set of experiments, such as Seahorse bioenergetic profiling and quantitative mitochondrial analyses. Huh7 cells exhibit transcriptional inactivation of p53, while HepG2 cells retain p53 functionality. Huh7 cells harbor a mutation in p53, a regulator of mitochondrial function, redox homeostasis, and apoptosis. Nevertheless, the role of p53 in NAFLD progression remains controversial; thus far, the interrelationship between p53 and NAFLD is not fully elucidated [43].

Studies have demonstrated that Huh7 cells serve as a valuable in vitro model for investigating the effects of insulin resistance on hepatic de novo lipogenesis [44] and possess robust fatty acid oxidation capacity [45]. We therefore consider it a useful preliminary screening model for our study. Further comparative studies are needed regarding identical concentrations of FFA treatment applied to both primary hepatocyte and other liver cancer cell lines. Cell line models mimic physiological and pathological conditions, but cannot fully replicate the complexities of the human liver. The final verification step must be carried out in primary hepatocytes, liver organoids or animal models. Key findings from this model must be verified in more advanced models. In vivo animal models will be necessary to test the relevance of observations of the complex processes underlying the progression from NAFL to non-alcoholic steatohepatitis.

FFA are principally an intermediate product of fat metabolism. The clinicopathological features of NAFLD are associated with the excessive deposition of FFA in hepatocytes, leading to steatosis and a series of damages to the nucleus and organelles within hepatocytes and other cells within the liver. While most NAFLD animal models effectively replicate hepatic steatosis and inflammation, developing models that exhibit severe liver fibrosis remains a challenge. Furthermore, modelling non-alcoholic steatohepatitis animal models—particularly those with liver fibrosis—is both time-consuming and costly, presenting additional obstacles for researchers. Cell lines can only mimic certain phenotypes related to hepatic steatosis, inflammation and liver fibrosis in

NAFLD. To investigate multiple phenotypes comprehensively, it is essential to establish various cell lines or co-culture systems; even 3-dimensional models may be required. Our research suggests that this Huh7 cell model provides a viable option for further exploration in co-culture systems aimed at studying alterations in energy metabolism and gene expression reprogramming during the progression of NAFLD.

Conclusions

We found that genes related to lipid storage and fatty acid metabolism are regulated under high-fat conditions in a hepatocyte model. Furthermore, bioenergetic analyses revealed an increase in respiratory ATP production and a decrease in glycolytic ATP production, keeping total ATP production rates unchanged. Taken together, these findings suggest that hepatocytes enhance mitochondrial fatty acid oxidation as a compensatory mechanism to reduce the fatty acid load and reduce glycolysis to balance energy metabolism under high fat loading. Failure to maintain this balance may lead to the progression of NAFL. These insights may aid in the development of new therapeutic strategies.

Abbreviations

ATP	Adenosine triphosphate
BP	Biological process
BSA	Bovine serum albumin
CCK-8	Cell Counting Kit-8
DMEM	Dulbecco's modified Eagle's medium
ECAR	Extracellular acidification rate
FFA	Free fatty acids
GO	Gene ontology
Huh7	Human hepatocellular carcinoma cell line
LC–MS/MS	Liquid chromatography-tandem mass spectrometry
NAFL	Non-alcoholic fatty liver
NAFLD	Non-alcoholic fatty liver disease
OCR	Oxygen consumption rate
PBS	Phosphate buffer saline
PER	Basal proton efflux rate
Rot/AA	Rotenone plus antimycin A
TPM	Transcripts per million

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12876-026-04658-z.

Supplementary Material 1.

Acknowledgements

We are grateful to PhD student Jasper Carlsen at Aarhus University, Research Unit for Molecular Medicine, for assisting with sample preparation and raw data filtering for proteomics. We are grateful to PhD student Jinrong Huang at the University of Copenhagen for helping with raw data filtering for mRNA sequencing when visiting the Department of Biomedicine, Aarhus University.

Authors' contributions

Conceptualization, Yonglun Luo, Peter Bross and Guangdong Tong; methodology, Lin Lin, Johan Palmfeldt, and Yonglun Luo; software, Xiao-Yu Zhou, Johan Palmfeldt, and Peter Bross; validation, Tianran Zhou, Yuhang Zhou, and Xiao-Yu Zhou; formal analysis, Tianran Zhou, Yuhang Zhou, Cagla Cömert, Xiao-Yu Zhou, Lin Lin, and Johan Palmfeldt; investigation, Tianran Zhou, and Cagla Cömert; resources, Cagla Cömert, Lin Lin, Lars Bolund, Johan Palmfeldt, Guangdong Tong, Yonglun Luo, and Peter Bross; data curation, Xiao-Yu Zhou, Johan Palmfeldt, and Peter Bross; writing—original draft preparation, Tianran Zhou, Xiao-Yu Zhou, Johan Palmfeldt, and Peter Bross; writing—review and editing, Tianran Zhou, Yuhang Zhou, Cagla Cömert, Xiao-Yu Zhou, Lin Lin, Lars Bolund, Johan Palmfeldt, Guangdong Tong, Yonglun Luo, and Peter Bross; visualization, Tianran Zhou, and Peter Bross; supervision, Guangdong Tong, Yonglun Luo, and Peter Bross; project administration, Lars Bolund, Guangdong Tong, Yonglun Luo, and Peter Bross; funding acquisition, Tianran Zhou, and Guangdong Tong. All the authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by grants from National Natural Science Foundation of China [82204998, 81974558], Sanming Project of Medicine in Shenzhen [SZZYSM202411013], Shenzhen Science and Technology Program [ZDSYS20210623092000002], GuangDong Basic and Applied Basic Research Foundation [2021A1515110645], and International Program for Postgraduates, Guangzhou University of Chinese Medicine.

Data availability

The raw RNA-seq data from this study have been submitted to the European Nucleotide Archive (ENA; https://www.ebi.ac.uk/ena) under accession number PRJEB81549. The mass spectrometry proteomics data have been deposited in the ProteomeXchange Consortium via the PRIDE partner repository (https://www.ebi.ac.uk/pride/), with the dataset identifier PXD057281.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication.

Not applicable.

Competing interests

The authors declare no competing interests.

Author details

[1]Department of Hepatology, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen 518000, China
[2]Research Unit for Molecular Medicine, Department of Clinical Medicine, Faculty of Health, Aarhus University, and Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus 8200, Denmark
[3]Department of Hepatology, Shenzhen Traditional Chinese Medicine Hospital Affiliated to Nanjing University of Chinese Medicine, Shenzhen 518000, China
[4]Department of Biomedicine, Aarhus University, Aarhus 8000, Denmark
[5]Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus 8200, Denmark
[6]Lars Bolund Institute of Regenerative Medicine, Qingdao-Europe Advanced Institute for Life Sciences, BGI-Qingdao, BGI-Shenzhen, Qingdao 266555, China

Received: 12 November 2025 / Accepted: 28 January 2026
Published online: 07 February 2026

References

1. Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M. From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol. 2019;16:411–28. https://doi.org/10.1038/s41575-019-0145-7.
2. Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023. https://doi.org/10.1016/j.jhep.2023.06.003. :S0168-8278(23)00418-X.
3. Eslam M, Sanyal AJ, George J, International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty

liver disease. Gastroenterology. 2020;158:1999–2014.e1. https://doi.org/10.1053/j.gastro.2019.11.312.
4. Li M, Xu C, Shi J, Ding J, Wan X, Chen D, et al. Fatty acids promote fatty liver disease via the dysregulation of 3-mercaptopyruvate sulfurtransferase/hydrogen sulfide pathway. Gut. 2018;67:2169–80. https://doi.org/10.1136/gutjnl-2017-313778.
5. Sunny NE, Bril F, Cusi K. Mitochondrial adaptation in nonalcoholic fatty liver disease: novel mechanisms and treatment strategies. Trends Endocrinol Metab. 2017;28:250–60. https://doi.org/10.1016/j.tem.2016.11.006.
6. Zhou T, Cömert C, Zhou X, Lin L, Bolund L, Palmfeldt J et al. Energy metabolism adaptations and gene expression reprogramming in a cellular MAFLD model. 2021;:2021.11.08.467719. https://doi.org/10.1101/2021.11.08.467719
7. Chavez-Tapia NC, Rosso N, Tiribelli C. Effect of intracellular lipid accumulation in a new model of non-alcoholic fatty liver disease. BMC Gastroenterol. 2012;12:20. https://doi.org/10.1186/1471-230X-12-20.
8. Ruhanen H, Nidhina Haridas PA, Eskelinen EL, Eriksson O, Olkkonen VM, Käkelä R. Depletion of TM6SF2 disturbs membrane lipid composition and dynamics in HuH7 hepatoma cells. Biochim Et Biophys Acta - Mol Cell Biology Lipids. 2017;1862:676–85. https://doi.org/10.1016/j.bbalip.2017.04.004.
9. Rao J, Peng L, Liang X, Jiang H, Geng C, Zhao X, et al. Performance of copy number variants detection based on whole-genome sequencing by DNBSEQ platforms. BMC Bioinformatics. 2020;21:518. https://doi.org/10.1186/s12859-020-03859-x.
10. Patterson J, Carpenter EJ, Zhu Z, An D, Liang X, Geng C, et al. Impact of sequencing depth and technology on de Novo RNA-Seq assembly. BMC Genomics. 2019;20:604. https://doi.org/10.1186/s12864-019-5965-x.
11. Wagner GP, Kin K, Lynch VJ. Measurement of mRNA abundance using RNA-seq data: RPKM measure is inconsistent among samples. Theory Biosci. 2012;131:281–5. https://doi.org/10.1007/s12064-012-0162-3.
12. Anders S, Huber W. Differential expression analysis for sequence count data. Genome Biol. 2010;11:R106. https://doi.org/10.1186/gb-2010-11-10-r106.
13. Edhager AV, Povlsen JA, Løfgren B, Bøtker HE, Palmfeldt J. Proteomics of the rat myocardium during development of type 2 diabetes mellitus reveals progressive alterations in major metabolic pathways. J Proteome Res. 2018;17:2521–32. https://doi.org/10.1021/acs.jproteome.8b00276.
14. Palmfeldt J, Vang S, Stenbroen V, Pedersen CB, Christensen JH, Bross P, et al. Mitochondrial proteomics on human fibroblasts for identification of metabolic imbalance and cellular stress. Proteome Sci. 2009;7:20. https://doi.org/10.1186/1477-5956-7-20.
15. Paternoster V, Svanborg M, Edhager AV, Rajkumar AP, Eickhardt EA, Pallesen J, et al. Brain proteome changes in female Brd1+/- mice unmask dendritic spine pathology and show enrichment for schizophrenia risk. Neurobiol Dis. 2019;124:479–88. https://doi.org/10.1016/j.nbd.2018.12.011.
16. Levin Y. The role of statistical power analysis in quantitative proteomics. Proteomics. 2011;11:2565–7. https://doi.org/10.1002/pmic.201100033.
17. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4:44–57. https://doi.org/10.1038/nprot.2008.211.
18. Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009;37:1–13. https://doi.org/10.1093/nar/gkn923.
19. Rath S, Sharma R, Gupta R, Ast T, Chan C, Durham TJ, et al. MitoCarta3.0: an updated mitochondrial proteome now with sub-organelle localization and pathway annotations. Nucleic Acids Res. 2021;49:D1541–7. https://doi.org/10.1093/nar/gkaa1011.
20. Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47:D607–13. https://doi.org/10.1093/nar/gky1131.
21. Crowley LC, Marfell BJ, Waterhouse NJ. Analyzing Cell Death by Nuclear Staining with Hoechst 33342. Cold Spring Harb Protoc. 2016;2016. https://doi.org/10.1101/pdb.prot087205
22. Xie Z, Bailey A, Kuleshov MV, Clarke DJB, Evangelista JE, Jenkins SL, et al. Gene set knowledge discovery with enrichr. Curr Protocols. 2021;1:e90. https://doi.org/10.1002/cpz1.90.
23. Ms B, Jl AR. Retrospective on cholesterol homeostasis: the central role of Scap. Annu Rev Biochem. 2018. https://doi.org/10.1146/annurev-biochem-062917-011852. 87.
24. Xiao M, Zhong H, Xia L, Tao Y, Yin H. Pathophysiology of mitochondrial lipid oxidation: role of 4-hydroxynonenal (4-HNE) and other bioactive lipids in mitochondria. Free Radic Biol Med. 2017;111:316–27. https://doi.org/10.1016/j.freeradbiomed.2017.04.363.
25. Luangmonkong T, Suriguga S, Mutsaers HAM, Groothuis GMM, Olinga P, Boersema M. Targeting oxidative stress for the treatment of liver fibrosis. Rev Physiol Biochem Pharmacol. 2018;175:71–102. https://doi.org/10.1007/112_2018_10.
26. Yu S, Song J-H, Kim HS, Hong S, Park SK, Park SH, et al. Patulin alleviates hepatic lipid accumulation by regulating lipogenesis and mitochondrial respiration. Life Sci. 2023;326:121816. https://doi.org/10.1016/j.lfs.2023.121816.
27. Hsu M-C, Guo B-C, Chen C-H, Hu P-A, Lee T-S. Apigenin ameliorates hepatic lipid accumulation by activating the autophagy-mitochondria pathway. J Food Drug Anal 29:240–54. https://doi.org/10.38212/2224-6614.3269
28. Longhitano L, Distefano A, Musso N, Bonacci P, Orlando L, Giallongo S, et al. (+)-Lipoic acid reduces mitochondrial unfolded protein response and attenuates oxidative stress and aging in an in vitro model of non-alcoholic fatty liver disease. J Transl Med. 2024;22:82. https://doi.org/10.1186/s12967-024-04880-x.
29. Li J, Wang T, Liu P, Yang F, Wang X, Zheng W, et al. Hesperetin ameliorates hepatic oxidative stress and inflammation via the PI3K/AKT-Nrf2-ARE pathway in oleic acid-induced HepG2 cells and a rat model of high-fat diet-induced NAFLD. Food Funct. 2021;12:3898–918. https://doi.org/10.1039/d0fo02736g.
30. Mashek DG. Hepatic lipid droplets: A balancing act between energy storage and metabolic dysfunction in NAFLD. Mol Metabolism. 2021;50:101115. https://doi.org/10.1016/j.molmet.2020.101115.
31. Tsai T-H, Chen E, Li L, Saha P, Lee H-J, Huang L-S, et al. The constitutive lipid droplet protein PLIN2 regulates autophagy in liver. Autophagy. 2017;13:1130–44. https://doi.org/10.1080/15548627.2017.1319544.
32. Kim M-S, Lee K-T, Iseli TJ, Hoy AJ, George J, Grewal T, et al. Compound K modulates fatty acid-induced lipid droplet formation and expression of proteins involved in lipid metabolism in hepatocytes. Liver Int. 2013;33:1583–93. https://doi.org/10.1111/liv.12287.
33. F H, Mb M. The offspring from rats fed a fatty diet display impairments in the activation of liver peroxisome proliferator activated receptor alpha and features of fatty liver disease. Mol Cell Endocrinol. 2020;511. https://doi.org/10.1016/j.mce.2020.110818.
34. Chen Y, Zhu Z, Zhang L, Wang J, Ren H. Roles of N6-methyladenosine epitranscriptome in non-alcoholic fatty liver disease and hepatocellular carcinoma. Smart Med. 2023;2:e20230008. https://doi.org/10.1002/SMMD.20230008.
35. Baralle M, Baralle FE. Alternative splicing and liver disease. Ann Hepatol. 2021;26:100534. https://doi.org/10.1016/j.aohep.2021.100534.
36. Xu K, Wu T, Xia P, Chen X, Yuan Y. Alternative splicing: a Bridge connecting NAFLD and HCC. Trends Mol Med. 2023;29:859–72. https://doi.org/10.1016/j.molmed.2023.07.001.
37. Jobbins AM, Haberman N, Artigas N, Amourda C, Paterson HAB, Yu S, et al. Dysregulated RNA polyadenylation contributes to metabolic impairment in non-alcoholic fatty liver disease. Nucleic Acids Res. 2022;50:3379–93. https://doi.org/10.1093/nar/gkac165.
38. Be MSSSSS, Lf MMC. Rapid changes in chromatin structure during dedifferentiation of primary hepatocytes in vitro. Genomics. 2022;114. https://doi.org/10.1016/j.ygeno.2022.110330.
39. Kiamehr M, Heiskanen L, Laufer T, Düsterloh A, Kahraman M, Käkelä R, et al. Dedifferentiation of primary hepatocytes is accompanied with reorganization of lipid metabolism indicated by altered molecular lipid and MiRNA profiles. Int J Mol Sci. 2019;20:2910. https://doi.org/10.3390/ijms20122910.
40. Lu T-Y, Ji Y, Lyu C, Shen EN, Sun Y, Xiang Y, et al. Bioprinted high cell density liver model with improved hepatic metabolic functions. Biomaterials. 2025;320:123256. https://doi.org/10.1016/j.biomaterials.2025.123256.
41. Nagarajan SR, Paul-Heng M, Krycer JR, Fazakerley DJ, Sharland AF, Hoy AJ. Lipid and glucose metabolism in hepatocyte cell lines and primary mouse hepatocytes: a comprehensive resource for in vitro studies of hepatic metabolism. Am J Physiol Endocrinol Metab. 2019;316:E578–89. https://doi.org/10.1152/ajpendo.00365.2018.
42. Pj G, Cj G, C P. In vitro cellular models of human hepatic fatty acid metabolism: differences between Huh7 and HepG2 cell lines in human and fetal bovine culturing serum. Physiological Rep. 2017;5. https://doi.org/10.14814/phy2.13532.
43. p53 as. A double-edged sword in the progression of non-alcoholic fatty liver disease. Life Sci. 2018;215:64–72. https://doi.org/10.1016/j.lfs.2018.10.051.

44. Tarekegn LH, Shuster SO, Davis CM. Insulin-resistant Huh-7 cells as a model for nonalcoholic fatty liver disease. Biophys J. 2024;123:411a. https://doi.org/10.1016/j.bpj.2023.11.2515.
45. Gunn PJ, Green CJ, Pramfalk C, Hodson L. In vitro cellular models of human hepatic fatty acid metabolism: differences between Huh7 and HepG2 cell lines in human and fetal bovine culturing serum. Physiol Rep. 2017;5:e13532. https://doi.org/10.14814/phy2.13532.

Publisher's note